Prevalence of SLCO1B1 single nucleotide variations and their association with hypercholesterolaemia in hypercholesterolemic patients in Gauteng, South Africa

References

• Algharably EA-H, Filler I, Rosenfeld S, Grabowski K, Kreutz R. 2017. Statin intolerance–a question of definition. Expert Opin Drug Saf. 16(1):55–63.
   PubMed Web of Science ®Google Scholar
• Alwi ZB. 2005. The use of SNPs in pharmacogenomics studies. Malays J Med Sci. 12(2):4–12.
   PubMedGoogle Scholar
• Ballantyne CM, Blazing MA, Hunninghake DB, Davidson MH, Yuan Z, DeLucca P, Ramsey KE, Hustad CM, Palmisano J. 2003. Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS). Am Heart J. 146(5):862–869.
   PubMed Web of Science ®Google Scholar
• Banach M, Rizzo M, Toth PP, Farnier M, Davidson MH, Al-Rasadi K, Aronow WS, Athyros V, Djuric DM, Ezhov MV, et al. 2015. Statin intolerance–an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Expert Opin Drug Saf. 14(6):935–955.
   PubMed Web of Science ®Google Scholar
• Bar SL, Holmes DT, Frohlich J. 2007. Asymptomatic hypothyroidism and statin-induced myopathy. Can Fam Physician. 53(3):428–431.
   PubMed Web of Science ®Google Scholar
• Bonfim MR, Oliveira ASB, do Amaral SL, Monteiro HL. 2015. Treatment of dyslipidemia with statins and physical exercises: recent findings of skeletal muscle responses. Arq Bras Cardiol. 104(4):324–331.
   PubMed Web of Science ®Google Scholar
• Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. 2005. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients—the PRIMO study. Cardiovasc Drugs Ther. 19(6):403–414.
   PubMed Web of Science ®Google Scholar
• Brunham LR, Lansberg PJ, Zhang L, Miao F, Carter C, Hovingh GK, Visscher H, Jukema JW, Stalenhoef AF, Ross CJD, et al. 2012. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J. 12(3):233–237.
   PubMed Web of Science ®Google Scholar
• American College of Cardiology. 2013. ACC statin intolerance app - American College of Cardiology. [Accessed 2020 Oct 9]. https://www.acc.org/StatinIntoleranceApp.
   Google Scholar
• Carr D, O'meara H, Jorgensen A, Campbell J, Hobbs M, McCann G, Van Staa T, Pirmohamed M. 2013. SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink. Clin Pharmacol Ther. 94(6):695–701.
   PubMed Web of Science ®Google Scholar
• Cham S, Evans MA, Denenberg JO, Golomb BA. 2010. Statin‐associated muscle‐related adverse effects: a case series of 354 patients. Pharmacotherapy. 30(6):541–553.
   PubMed Web of Science ®Google Scholar
• Cohen JD, Brinton EA, Ito MK, Jacobson TA. 2012. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol. 6(3):208–215.
   PubMed Web of Science ®Google Scholar
• Consortium IH. 2003. The international HapMap project. Nature. 426:789.
   PubMed Web of Science ®Google Scholar
• Cuevas A, Fernández C, Ferrada L, Zambrano T, Rosales A, Saavedra N, Salazar LA. 2016. HMGCR rs17671591 SNP determines lower plasma LDL‐C after atorvastatin therapy in Chilean individuals. Basic Clin Pharmacol Toxicol. 118(4):292–297.
   PubMed Web of Science ®Google Scholar
• De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G. et al. 2003. European guidelines on cardiovascular disease prevention in clinical practiceThird Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts. Eur Heart J. 24(17):1601–1610.
   PubMed Web of Science ®Google Scholar
• Dendramis G. 2011. Interindividual differences in the response to statin therapy and gene polymorphisms related to myopathy during statin therapy. G Ital Cardiol (Rome). 12(3):182–185. 2006).
   PubMedGoogle Scholar
• Deng JW, Song I-S, Shin HJ, Yeo C-W, Cho D-Y, Shon J-H, Shin J-G. 2008. The effect of SLCO1B1* 15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1* 15. Pharmacogenet Genom. 18(5):424–433.
   PubMed Web of Science ®Google Scholar
• Grigorova M, Laan M, Adler M, Punab M, Poolamets O, Vihljajev V. 2017. Genetics of sex hormone-binding globulin and testosterone levels in fertile and infertile men of reproductive age. J Endocrine Soc. 1(6):560–576.
   PubMed Web of Science ®Google Scholar
• Group HPSC. 2002. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial. Lancet. 360:7–22.
   PubMed Web of Science ®Google Scholar
• Guo Q, Si Y, Su M, Fan M, Lin J, Memon NH, Fang D. 2017. PCSK9 rs7552841 is associated with plasma lipids profiles in female Chinese adolescents without posttraumatic stress disorder. Biosci Trends. 11(5):542–549.
   PubMed Web of Science ®Google Scholar
• Hanai J-i, Cao P, Tanksale P, Imamura S, Koshimizu E, Zhao J, Kishi S, Yamashita M, Phillips PS, Sukhatme VP, et al. 2007. The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity. J Clin Invest. 117(12):3940–3951.
   PubMed Web of Science ®Google Scholar
• Health24. 2020. Cholesterol | High Cholesterol Levels. [Accessed 2020 Oct 11]. https://www.health24.com/Medical/cholesterol..
   Google Scholar
• Hedenmalm K, Alvan G, Öhagen P, Dahl M-L. 2010. Muscle toxicity with statins. Pharmacoepidem Drug Safe. 19(3):223–231.
   PubMed Web of Science ®Google Scholar
• Holloway JW, Prescott SL. 2017. Chapter 2 - the origins of allergic disease. In: O'Hehir RE, Holgate ST, Sheikh A, editors. Middleton's allergy essentials. Philadelphia, United States: Elsevier; p. 29–50.
   Google Scholar
• Hubáček JA, Dlouhá D, Adámková V, Zlatohlavek L, Viklický O, Hrubá P, Češka R, Vrablík M. 2015. SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population. Med Sci Monit. 21:1454–1459.
   PubMed Web of Science ®Google Scholar
• Hunter J, Hirst BH. 1997. Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption. Adv Drug Delivery Rev. 25(2–3):129–157.
   Web of Science ®Google Scholar
• Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, McKenney JM, Grundy SM, Gill EA, Wild RA, others, et al. 2014. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 – executive summary. J Clin Lipidol. 8(5):473–488. and
   PubMed Web of Science ®Google Scholar
• Johnson JE, Wold BJ, Hauschka SD. 1989. Muscle creatine kinase sequence elements regulating skeletal and cardiac muscle expression in transgenic mice. Mol Cell Biol. 9(8):3393–3399.
   PubMed Web of Science ®Google Scholar
• Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW. 2003. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR**STELLAR = Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin. Trial). The American Journal of Cardiology. 92(2):152–160.
   PubMed Web of Science ®Google Scholar
• Jones PMD, Kafonek SMD, Ip L, Hunninghake DMD. 1998. Comparative dose efficacy study of Atorvastatin Versus Simvastatin, Pravastatin, Lovastatin, Fluvastatin in patients with hypercholesterolemia (The CURVES study) fn1. Am J Cardiol. 81:582–587.
   PubMed Web of Science ®Google Scholar
• Kajinami K, Akao H, Polisecki E, Schaefer EJ. 2005. Pharmacogenomics of statin responsiveness. Am J Cardiol. 96(9):65–70.
   Web of Science ®Google Scholar
• Kalliokoski A, Niemi M. 2009. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 158(3):693–705.
   PubMed Web of Science ®Google Scholar
• Kellick KA, Bottorff M, Toth PP. 2014. A clinician's guide to statin drug-drug interactions. J Clin Lipidol. 8:S30–S46.
   PubMed Web of Science ®Google Scholar
• Khine H, Yuet WC, Adams-Huet B, Ahmad Z. 2016. Statin-associated muscle symptoms and SLCO1B1 rs4149056 genotype in patients with familial hypercholesterolemia. Am Heart J. 179:1–9.
   PubMed Web of Science ®Google Scholar
• Klug WS. 2012. Concepts of genetics. San Francisco (CA): Pearson Education.
   Google Scholar
• König J, Cui Y, Nies AT, Keppler D. 2000. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver Physiol. 278(1):G156–G64.
   PubMed Web of Science ®Google Scholar
• Kotlęga D, Gołąb-Janowska M, Masztalewicz M, Ciećwież S, Nowacki P. 2016. Association between selected gene polymorphisms and statin metabolism, risk of ischemic stroke and cardiovascular disorders. Postepy Hig Med Dosw. 2016;70:435–447.
   Web of Science ®Google Scholar
• Lee E, Ryan S, Birmingham B, Zalikowski J, March R, Ambrose H, Moore R, Lee C, Chen Y, Schneck D. 2005. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther. 78(4):330–341.
   PubMed Web of Science ®Google Scholar
• Li L-M, Chen L, Deng G-H, Tan W-T, Dan Y-J, Wang R-Q, Chen W-S. 2012. SLCO1B1 *15 haplotype is associated with rifampin-induced liver injury . Mol Med Rep. 6(1):75–82.
   PubMed Web of Science ®Google Scholar
• Lin R, Wang X, Zhou W, Fu W, Wang Y, Huang W, Jin L. 2011. Association of polymorphisms in the solute carrier organic anion transporter family member 1B1 gene with essential hypertension in the Uyghur population. Ann Hum Genet. 75(2):305–311.
   PubMed Web of Science ®Google Scholar
• Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R, 2008. SLCO1B1 variants and statin-induced myopathy–a genomewide study. N Engl J Med. 359:789–799.
   PubMed Web of Science ®Google Scholar
• Liutkeviciene R, Vilkeviciute A, Slavinskaite A, Petrauskaite A, Tatarunas V, Kriauciuniene L. 2018. Evaluation of serum SLCO1B1 levels and genetic variants of SLCO1B1 rs4149056 and rs2306283 in patients with early and exudative age-related macular degeneration. Gene. 676:139–145.
   PubMed Web of Science ®Google Scholar
• Luo J-Q, He F-Z, Wang Z-M, Sun N-L, Wang L-Y, Tang G-F, Liu M-Z, Li Q, Chen X-P, Liu Z-Q, et al. 2015. SLCO1B1 variants and angiotensin converting enzyme inhibitor (enalapril)-induced cough: a pharmacogenetic study. Sci Rep. 5:17253.
   PubMed Web of Science ®Google Scholar
• Mancini GBJ, Baker S, Bergeron J, Fitchett D, Frohlich J, Genest J, Gupta M, Hegele RA, Ng D, Pearson GJ, et al. 2016. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian consensus working group update (2016). Can J Cardiol. 32(7):S35–S65.
   PubMed Web of Science ®Google Scholar
• Martin SS, Blumenthal RS, Miller M. 2012. LDL cholesterol: the lower the better. Med Clin North Am. 96(1):13–26.
   PubMed Web of Science ®Google Scholar
• Melo MS, Balanco L, Branco CC, Mota-Vieira L. 2015. Genetic variation in key genes associated with statin therapy in the Azores Islands (Portugal) healthy population. Ann Hum Biol. 42(3):285–291.
   Web of Science ®Google Scholar
• Méndez L, Lagoa M, Quiroga T, Margozzini P, Azócar L, Molina HR, Vera A, Villarroel L, Arrese M, Hampe J, et al. 2013. [Prevalence of Gilbert syndrome and its genetic determinants in Chile]. Rev Med Chil. 141(10):1266–1274.
   PubMed Web of Science ®Google Scholar
• Moghadam-Kia S, Oddis CV, Aggarwal R. 2016. Approach to asymptomatic creatine kinase elevation. Cleve Clin J Med. 83(1):37–42.
   PubMed Web of Science ®Google Scholar
• Mombelli G. 2013. Statin muscle toxicity and genetic risk factors. Int J Genomics. 1(2):1–5.
   Google Scholar
• Musunuru K, Kathiresan S. 2008. HapMap and mapping genes for cardiovascular disease. Circ Genomic Precis Med. 1:66–71.
   Google Scholar
• Mwinyi J, Köpke K, Schaefer M, Roots I, Gerloff T. 2008. Comparison of SLCO1B1 sequence variability among German, Turkish, and African populations. Eur J Clin Pharmacol. 64(3):257–266.
   PubMed Web of Science ®Google Scholar
• Nagy A, Sipeky C, Szalai R, Melegh BI, Matyas P, Ganczer A, Toth K, Melegh B. 2015. Marked differences in frequencies of statin therapy relevant SLCO1B1 variants and haplotypes between Roma and Hungarian populations. BMC Genet. 16(1):108.
   PubMed Web of Science ®Google Scholar
• Newman CB, Palmer G, Silbershatz H, Szarek M. 2003. Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. The American Journal of Cardiology. 92(6):670–676.
   PubMed Web of Science ®Google Scholar
• Nicholson P, Yepiskoposyan H, Metze S, Orozco RZ, Kleinschmidt N, Mühlemann O. 2010. Nonsense-mediated mRNA decay in human cells: mechanistic insights, functions beyond quality control and the double-life of NMD factors. Cell Mol Life Sci. 67(5):677–700.
   PubMed Web of Science ®Google Scholar
• Niemi M, Pasanen MK, Neuvonen PJ. 2011. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 63(1):157–181.
   PubMed Web of Science ®Google Scholar
• Nies AT, Niemi M, Burk O, Winter S, Zanger UM, Stieger B, Schwab M, Schaeffeler E. 2013. Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1. Genome Med. 5(1):1.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Dent-Acosta RE, Rosenson RS, Stroes E, Sattar N, Preiss D, Mancini GBJ, Ballantyne CM, Catapano A, Gouni-Berthold I, et al. 2016. Comparison of PCSK9 inhibitor evolocumab vs ezetimibe in statin‐intolerant patients: design of the goal achievement after utilizing an anti‐PCSK9 antibody in statin‐intolerant subjects 3 (GAUSS‐3) trial. Clin Cardiol. 39(3):137–144.
   PubMed Web of Science ®Google Scholar
• Oshiro C, Mangravite L, Klein T, Altman R. 2010. PharmGKB very important pharmacogene: SLCO1B1. Pharmacogenet Genomics. 20(3):211–216.
   PubMed Web of Science ®Google Scholar
• Pasanen MK, Backman JT, Neuvonen PJ, Niemi M. 2006. Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population. Eur J Clin Pharmacol. 62(6):409–415.
   PubMed Web of Science ®Google Scholar
• Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. 2006. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics. 16(12):873–879.
   PubMed Web of Science ®Google Scholar
• Pasternak RC, Smith SC, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. 2002. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol. 40(3):567–572.
   PubMed Web of Science ®Google Scholar
• Petrkova J, Taborsky M, Petrek M. 2018. Pharmacogenetics of cardiovascular disease: genetic variation and statin intolerance. In Genetic diversity and disease susceptibility. London, United Kingdom: IntechOpen.
   Google Scholar
• Puccetti L, Ciani F, Auteri A. 2010. Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study. Atherosclerosis. 211(1):28–29.
   PubMed Web of Science ®Google Scholar
• Robert F, Pelletier J. 2018. Exploring the impact of single-nucleotide polymorphisms on translation. Front Genet. 9:507.
   PubMed Web of Science ®Google Scholar
• Santos PCJL, Gagliardi ACM, Miname MH, Chacra AP, Santos RD, Krieger JE, Pereira AC. 2012. SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia. Eur J Clin Pharmacol. 68(3):273–279.
   PubMed Web of Science ®Google Scholar
• Santos PCJL, Soares RAG, Nascimento RM, Machado-Coelho GLL, Mill JG, Krieger JE, Pereira AC. 2011. SLCO1B1 rs4149056 polymorphism associated with statin-induced myopathy is differently distributed according to ethnicity in the Brazilian general population: Amerindians as a high-risk ethnic group. BMC Med Genet. 12(1):136.
   PubMed Web of Science ®Google Scholar
• Scandinavian Simvastatin Survival Study. 1994. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1383–1389.
   PubMed Web of Science ®Google Scholar
• Schachter M. 2005. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 19(1):117–125.
   PubMed Web of Science ®Google Scholar
• Shah RV, Goldfine AB. 2012. Statins and risk of new-onset diabetes mellitus. Circulation. 126(18):e282–e4.
   PubMed Web of Science ®Google Scholar
• Sinatra ST. 2003. Is cholesterol lowering with statins the gold standard for treating patients with cardiovascular risk and disease? South Med J. 96(3):220–223.
   PubMed Web of Science ®Google Scholar
• Snpedia.com. 2018. rs4149056 - SNPedia. [accessed 2018 Nov 18]. https://www.snpedia.com/index.php/Rs4149056.
   Google Scholar
• Stewart A. 2013. SLCO1B1 polymorphisms and statin-induced myopathy. PLoS Curr Evid Genomic Tests. 1st ed. doi: 10.1371/currents.eogt.d21e7f0c58463571bb0d9d3a19b82203.
   Google Scholar
• Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, et al. 2014. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 63(25 Pt B):2889–2934.
   PubMed Web of Science ®Google Scholar
• Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, Roden M, Stein E, Tokgözoğlu L, Nordestgaard BG, et al. 2015. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society consensus panel statement on assessment, aetiology and management. Eur Heart J. 36(17):1012–1022.
   PubMed Web of Science ®Google Scholar
• Thompson JF, Hyde CL, Wood LS, Paciga SA, Hinds DA, Cox DR, Hovingh GK, Kastelein JJ. 2009. Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the Treating to New Targets (TNT) cohort. Circ Genomic Precis Med. 2:173–181.
   Google Scholar
• Tirona RG, Leake BF, Merino G, Kim RB. 2001. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem. 276(38):35669–35675.
   PubMed Web of Science ®Google Scholar
• Toth PP, Patti AM, Giglio RV, Nikolic D, Castellino G, Rizzo M, Banach M. 2018. Management of statin intolerance in 2018: still more questions than answers. Am J Cardiovasc Drugs. 18(3):157–173.
   PubMed Web of Science ®Google Scholar
• Tozer TN, Rowland M. 2006. Introduction to pharmacokinetics and pharmacodynamics: the quantitative basis of drug therapy. Amsterdam: Lippincott Williams & Wilkins, Elsevier Health Sciences.
   Google Scholar
• Wilke RA, Ramsey LB, Johnson SG, Maxwell WD, McLeod HL, Voora D, Krauss RM, Roden DM, Feng Q, Cooper-Dehoff RM, et al. 2012. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther. 92(1):112–117. and
   PubMed Web of Science ®Google Scholar
• Zhang H, Plutzky J, Skentzos S, Morrison F, Mar P, Shubina M, Turchin A. 2013. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 158(7):526–534.
   PubMed Web of Science ®Google Scholar